Group 1 - Yibai Pharmaceutical received a notice from the Guizhou Provincial Drug Administration on September 16, 2025, lifting the suspension of production and sales of its children's cough syrup due to resolved safety concerns [1] - The company had previously suspended the production and sales of the children's cough syrup in August 2025, following a notification from the same authority [1] - Revenue from the children's cough syrup for the years 2021, 2022, 2023, and 2024 was 3.42 million, 4.32 million, 8.38 million, and 1.51 million respectively, accounting for 0.10%, 0.16%, 0.30%, and 0.07% of the company's total revenue during those years, indicating a relatively small impact on overall performance [1] Group 2 - In the first half of the year, the company reported a revenue of 993 million, a year-on-year decrease of 14.99%, and a net loss attributable to shareholders of 19.90 million [2] - The primary reason for the loss was a decrease in sales of major products, while costs remained higher than revenue; however, improved cost control measures led to a reduction in losses compared to the previous year [2] - The company is actively expanding into chemical drugs, traditional Chinese medicine, and biological drugs, focusing on building a robust R&D system and integrating advantageous resources for innovative drug development [2] Group 3 - The company is exploring existing products with unique or similar exclusivity and conducting research on ancient classic formula compound preparations [3] - Research efforts include safety re-evaluation studies for Ginkgo Biloba injection and quality studies for Aidi injection, with preliminary completion of quality standard enhancement for Ginkgo Biloba injection [3] - As of June 30, 2025, the company completed the registration of 412 new products, including 248 national standard products and 164 provincial standard products [3]